GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HighTide Therapeutics 2511.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

3.00

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2026

Net income

−CN¥275.8m

FY2021FY2026

Free cash flow

−CN¥193.0m

FY2021FY2026

Shareholders' equity

CN¥355.0m

FY2021FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Gross profit−CN¥7.0m—−CN¥2.0m−CN¥1.3m−CN¥1.8m—
Research and developmentCN¥185.2mCN¥363,525CN¥344.3mCN¥186.5mCN¥95.5mCN¥84.0m
Operating income−CN¥251.7m−CN¥444,754−CN¥456.4m−CN¥226.1m−CN¥152.6m−CN¥220.5m
Net income−CN¥275.8m−CN¥381,788−CN¥1.04bn−CN¥190.2m−CN¥255.6m−CN¥221.1m
Diluted earnings per share-0.57-0.00-2,295.80-369.54-496.44-0.47

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Total assetsCN¥637.4mCN¥559.9mCN¥795.0mCN¥855.8mCN¥898.2mCN¥778.6m
Cash and short-term investmentsCN¥581.2mCN¥490.5mCN¥735.7mCN¥828.3mCN¥882.8mCN¥765.3m
Total liabilitiesCN¥215.8mCN¥135.8mCN¥92.3mCN¥1.33bnCN¥1.21bnCN¥1.05bn
DebtCN¥134.3mCN¥77.9mCN¥16.4mCN¥1.27bnCN¥8.4mCN¥1.01bn
Shareholders' equityCN¥355.0mCN¥424.2mCN¥702.8m−CN¥470.5m−CN¥314.1m−CN¥272.3m
Shares outstanding480m510m0m1m1m473m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations−CN¥192.9m−CN¥294.8m−CN¥367.7m−CN¥172.7m−CN¥104.6m−CN¥90.5m
Capital spending−CN¥85,519−CN¥4.6m−CN¥885,101−CN¥186,864−CN¥2.0m−CN¥1.7m
Free cash flow−CN¥193.0m−CN¥299.5m−CN¥368.6m−CN¥172.9m−CN¥106.6m−CN¥92.3m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
Gross profit−CN¥3.5m———−CN¥2.9m—−CN¥1.1m—
Operating income−CN¥108.6m−CN¥147,969−CN¥196,726−CN¥113,674−CN¥248,089−CN¥143,459−CN¥277.9m−CN¥159,129
Net income−CN¥141.7m−CN¥139,045−CN¥170,843−CN¥98,718−CN¥210,997−CN¥122,009−CN¥420.9m−CN¥224,493
Diluted earnings per share-0.28-0.00-0.38-0.22-0.47-0.27-817.52-0.44
Cash from operations−CN¥51.0m−CN¥143.0m−CN¥107.0m—−CN¥187.0m—−CN¥213.0m—
Capital spending——−CN¥4.0m—————
Free cash flow——−CN¥111.0m—————
Total assetsCN¥637.4mCN¥610.7mCN¥559.9mCN¥647.1mCN¥621.8mCN¥663.7mCN¥792.7mCN¥854.3m
Cash and short-term investmentsCN¥581.2mCN¥539.7mCN¥490.5mCN¥566.9mCN¥524.1mCN¥601.4mCN¥733.5mCN¥791.3m
DebtCN¥146.6mCN¥115.0mCN¥77.9mCN¥60.6mCN¥28.5mCN¥5.8mCN¥16.4mCN¥6.6m
Shareholders' equityCN¥355.0mCN¥364.6mCN¥424.2mCN¥490.2mCN¥548.7mCN¥585.6mCN¥700.7mCN¥755.2m

Financial ratios

Data as of 5 Nov 2026

FY2026FY2025FY2024FY2023FY2022
Return on equity-79.8%-90.0%-133.7%40.4%81.4%
Return on assets-44.4%-68.2%-118.1%-22.2%-28.5%
Free cash flow yield-10.8%-19.2%-26.9%-11.1%-5.8%
Earnings growth-35.8%-59.4%393.8%-14.0%—
Current ratio5.41x4.67x9.76x0.64x27.17x
Debt to equity0.38x0.15x0.01x-2.70x-0.03x
Equity ratio55.7%75.8%88.4%-55.0%-35.0%
Interest coverage-97.09x-289.93x-1014.11x-530.71x-29.17x
Buybacks as a share of market value0.0%-12.5%12.2%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income3.6%2.7%—
Net income13.2%4.5%—

Valuation history

At each fiscal year end

FY2026FY2025FY2023
Price to earnings-5.3-3411.8-0.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.